• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: GW Pharmaceuticals     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatPharmaceuticalCompaniesOfTheUnitedKingdom, within Data Space : dbpedia.org associated with source document(s)

Type: Thingcompanyschema:Organizationdul:Agentdul:SocialPersonagentwikidata:Q24229398OrganizationBusiness enterpriseyago:WikicatBiotechnologyCompaniesOfTheUnitedKingdomyago:WikicatCompaniesEstablishedIn1998yago:WikicatCompaniesListedOnNASDAQyago:WikicatCompaniesListedOnTheLondonStockExchangeyago:Abstraction100002137yago:Company108058098yago:DrugCompany108002578yago:Group100031264yago:Institution108053576yago:Organization108008335yago:YagoLegalActoryago:YagoLegalActorGeoyago:YagoPermanentlyLocatedEntityorganisationyago:SocialGroup107950920yago:WikicatPharmaceuticalCompaniesyago:WikicatPharmaceuticalCompaniesOfTheUnitedKingdom New Facet based on Instances of this Class

GW Pharmaceuticals is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.